Tuesday, September 20, 2016

Oxymetazoline Hydrochloride


Class: Vasoconstrictors
VA Class: NT100
CAS Number: 2315-02-8
Brands: Afrin, Dristan 12 Hour, Duramist Plus, Duration 12 Hour, 4-Way 12 Hour Long Lasting, Neo-Synephrine 12 Hour, Nostrilla12 Hour Nasal Decongestant, Vicks Sinex 12 Hour Nasal Decongestant, Visine L.R. Eye Drops

Introduction

Vasoconstrictor;a an imidazoline-derivative sympathomimetic amine.a


Uses for Oxymetazoline Hydrochloride


Nasal Congestion


Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies.111


As effective as other topical vasoconstrictors.a


Labeled and has been used for self-medication for temporary relief of nasal congestion associated with sinusitis;107 111 however, efficacy data are lacking and/or controversial.107 108 109 In October 2005, FDA issued final rule to remove this indication from labeling of OTC nasal decongestants.107 Compliance date for preparations with annual sales <$25,000 is October 11, 2007; compliance date for all other preparations is April 11, 2007.107


Conjunctival Congestion


Self-medication for temporary relief of ocular redness due to minor irritation.112


Otitic Barotrauma


Has been used for self-medication for symptomatic prevention of otitic barotrauma† (aerotitis [barotitis] media);101 103 105 however, no more effective than placebo.101


Oxymetazoline Hydrochloride Dosage and Administration


Administration


Administer topically to nasal mucosa or conjunctiva.a 111 112


Intranasal Administration


Administer nasal solution intranasally as drops, sprays, or nasal pumps.a Nasal sprays may be preferable to drops due to decreased risk of swallowing of drug and resultant systemic absorption.a


Prior to initial use of metered sprays, prime nasal inhaler by depressing the pump firmly several times.a


Apply drops to dependent (lower) nostril while in a lateral, head-low position.a Remain in the same position for 5 minutes, then apply drops to the other nostril in a similar manner.a Alternatively, instill drops while in a reclining position, with head tilted back as far as possible.a


Administer nasal spray or pump into each nostril while head is erect.a


Ophthalmic Administration


Administer ophthalmic solution topically to the conjunctiva.a 112


Avoid contamination of the dropper tip.112


Remove contact lenses before administering ophthalmic solution.a 112


Do not administer discolored or cloudy solutions.112


Dosage


Available as oxymetazoline hydrochloride; dosage expressed in terms of the salt.111 112


Pediatric Patients


Nasal Congestion

Intranasal

For self-medication in children ≥6 years of age: 2 or 3 drops or sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.a 111


Conjunctival Congestion

Ophthalmic

For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.112


Adults


Nasal Congestion

Intranasal

For self-medication: 2 or 3 drops or sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.a 111


Conjunctival Congestion

Ophthalmic

For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.112


Prescribing Limits


Pediatric Patients


Nasal Congestion

Intranasal

Self-medication in children ≥6 years of age: Maximum of 2 times (2 doses) in a 24-hour period.111 (See Advice to Patients.)


Adults


Nasal Congestion

Intranasal

Self-medication: Maximum of 2 times (2 doses) in a 24-hour period.111 (See Advice to Patients.)


Cautions for Oxymetazoline Hydrochloride


Contraindications



  • Known hypersensitivity to oxymetazoline or any ingredient in the formulation.a




  • Known sensitivity to the pharmacologic effects of adrenergic drugs.a



Warnings/Precautions


General Precautions


Overuse

Possible irritation of nasal mucosa and adverse systemic effects (particularly in children) with excessive dosage and/or prolonged or too frequent intranasal use.a Possible rebound nasal congestion or ocular hyperemia (redness);a 111 112 avoid prolonged use.a (See Advice to Patients.)


Sympathomimetic Effects

With intranasal use, possible headache, hypertension, cardiac irregularities (e.g., palpitation, reflex bradycardia), nervousness, nausea, dizziness, and insomnia.a Use with caution and under direction of a clinician in patients with thyroid disease (e.g., hyperthyroidism), heart disease (including angina), hypertension, advanced arteriosclerotic conditions, or diabetes mellitus; in patients experiencing difficulty in urination secondary to prostatic enlargement; or in patients receiving monoamine oxidase (MAO) inhibitors.a 111


Glaucoma

Patients with narrow-angle glaucoma should consult a clinician before using ophthalmic solution.112


Specific Populations


Pregnancy

Category C.114


Lactation

Not known whether oxymetazoline is distributed into milk.114 Use with caution in nursing women.113


Pediatric Use

0.05% nasal solution or 0.025% ophthalmic solution not recommended for self-medication in children <6 years of age.111 112


Possible irritation of nasal mucosa and adverse systemic effects (including profound CNS depression) associated with excessive dosage, prolonged or too frequent use, or inadvertent ingestion of nasal solution.a


Common Adverse Effects


Nasal solution: transient burning, stinging, sneezing, increased nasal discharge or dryness of nasal mucosa.a 111


Oxymetazoline Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Occasionally, absorption may be sufficient to produce systemic effects.a


Onset


Following intranasal administration, local vasoconstriction usually occurs within 5–10 minutes.a


Following ocular administration, local vasoconstriction usually occurs within minutes.a


Duration


Following intranasal administration, local vasoconstriction persists for 5–6 hours, with gradual decline over the next 6 hours.a


Following ophthalmic administration, local vasoconstriction persists for up to 6 hours.a


Stability


Storage


Nasal


Solution

Room temperature (<40°C); avoid freezing.a 111 Protect from light.111


Ophthalmic


Solution

15–30°C;112 do not store in aluminum containers.a


ActionsActions



  • Structurally and pharmacologically related to naphazoline, tetrahydrozoline, and xylometazoline.a




  • Directly stimulates α-adrenergic receptors; exerts little or no effect on β-adrenergic receptors.a




  • Constricts dilated arterioles, reduces nasal blood flow and congestion, and opens obstructed eustachian ostia.a Temporarily relieves nasal and conjunctival congestion following topical application.a



Advice to Patients



  • With intranasal use, importance of discontinuing drug and consulting a clinician if nasal congestion worsens or persists for >3 days.111




  • With ophthalmic use, importance of discontinuing drug and consulting a clinician if ocular pain or visual changes occur or if ocular redness or irritation worsens or persists for >72 hours.112




  • Overuse of nasal solution may cause recurrence or exacerbation of nasal congestion;111 overuse of ophthalmic solution may produce increased redness of the eye.112




  • Importance of removing contact lenses prior to administration of ophthalmic solution.a 112




  • Importance of avoiding contamination of the dropper, inhaler, or spray dispenser.a 111 112 Do not touch dropper tip to any surface;112 rinse inhaler/spray dispenser tip with hot water or wipe clean following use.a To minimize risk of spreading infections, do not share dropper, inhaler, or spray dispenser with other individuals.a 111




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.a




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a




  • Importance of informing patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name














































































Oxymetazoline Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Nasal



Solution



0.05%*



Afrin (with benzalkonium chloride, povidone, and propylene glycol; with or without menthol and regular drops and spray)



Schering-Plough



Afrin No Drip Extra Moisturizing 12 Hour Pump Mist (with benzalkonium chloride, benzyl alcohol, glycerin, and povidone)



Schering-Plough



Afrin No Drip Original 12 Hour Pump Mist (with benzalkonium chloride, benzyl alcohol, and povidone)



Schering-Plough



Afrin No Drip Severe Congestion 12 Hour Pump Mist (with benzalkonium chloride, benzyl alcohol, povidone, and propylene glycol)



Schering-Plough



Afrin No Drip Sinus 12 Hour Pump Mist (with benzalkonium chloride, benzyl alcohol, and propylene glycol)



Schering-Plough



Dristan 12 Hour Nasal Spray (with benzalkonium chloride and benzyl alcohol)



Wyeth



Duramist Plus 12 Hour Nasal Decongestant Spray (with benzalkonium chloride)



Pfeiffer



4-Way 12 Hour Long Lasting Spray (with benzalkonium chloride and phenylmercuric acetate)



Bristol-Myers Squibb



Nasal Decongestant Maximum Strength Spray (with benzalkonium chloride, povidone, and propylene glycol)



Taro



Neo-Synephrine 12 Hour Extra Moisturizing Spray (with benzalkonium chloride, glycerin, and phenylmercuric acetate)



Bayer



Neo-Synephrine 12 Hour Long Acting Spray (with benzalkonium chloride and phenylmercuric acetate)



Bayer



Nostrilla12 Hour Nasal Decongestant (with benzalkonium chloride; with metered pump spray)



Insight



Vicks Sinex 12 Hour Nasal Decongestant Spray (with benzalkonium chloride andwith regular or metered pump mist spray)



Procter & Gamble



Ophthalmic



Solution



0.025%



Visine L.R. Eye Drops (with benzalkonium chloride)



Pfizer



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions June 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References


Only references cited for selected revisions after 1984 are available electronically.



100. Csortan E, Jones J, Haan M et al. Efficacy of pseudoephedrine for the prevention of barotrauma during air travel. Ann Emerg Med. 1994; 23:1324-7. [IDIS 330837] [PubMed 8198308]



101. Jones JS, Sheffield W, White LJ et al. A double-blind comparison between oral pseudoephedrine and topical oxymetazoline in the prevention of barotrauma during air travel. Am J Emerg Med. 1998; 16:262-4. [IDIS 407003] [PubMed 9596428]



102. Brown M, Jones K, Krohmer J. Pseudoephedrine for the prevention of barotitis media: a controlled clinical trial in underwater divers. Ann Emerg Med. 1992; 21:849-52. [PubMed 1610044]



103. Capes JP and Tomaszewski C. Prophylaxis against middle ear barotrauma in US in hyperbaric oxygen therapy centers. Am J Emerg Med. 1996; 14:645-8. [PubMed 8906761]



104. Newton HB. Neurologic complications of scuba diving. Am Fam Physician. 2001; 63:2211-8. [PubMed 11417773]



105. Carlson S, Jones J, Brown M et al. Prevention of hyperbaric-associated middle ear barotrauma. Ann Emerg Med. 1992; 21:1468-71. [PubMed 1443845]



106. Bettes TN and McKenas DK. Medical advice for commercial air travelers. Am Fam Physician. 1999; 60:801-10. [PubMed 10498108]



107. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for over-the-counter nasal decongestant drug products. 21 CFR Parts 310 and 341. Final rule. [Docket No. 2004N- 0289] Fed Regist. 2005; 70:58974-7.



108. Spector SL, Bernstein IL, Li JT et al for the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol. 1998; 102(Suppl):S107-44. [PubMed 9847450]



109. American Academy of Pediatrics: subcommittee on management of sinusitis and committee on quality improvement. Clinical practice guideline: Management of sinusitis. Pediatrics. 2001; 108:798-808. [PubMed 11533355]



110. Benninger MS, Anon J, Mabry RL. The medical management of rhinosinusitis. Otolaryngol Head Neck Surg. 1997; 117(Suppl):S41-9. [PubMed 9334787]



111. Neo-Synephrine 12 Hour (oxymetazoline hydrochloride) 0.05% nasal solution prescribing information. In PDR.net [database online]. Montvale, NJ: Thomson Healthcare; 2003. Updated 2003 Oct.



112. Visine L.R. Long Lasting (oxymetazoline hydrochloride) 0.025% ophthalmic solution prescribing information. In PDR.net [database online]. Montvale, NJ: Thomson Healthcare; 2003. Updated 2003 Oct.



113. Wickersham, RM. Drug Facts and Comparisons. 2003. St Louis, MO: Facts and Comparisons; 2003: page 685.



114. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1227-8.



a. AHFS Drug Information 2003. McEvoy GK, ed. Oxymetazoline Hydrochloride. Bethesda, MD: American Society of Health System Pharmacists; 2004: 2723-5.



More Oxymetazoline Hydrochloride resources


  • Oxymetazoline Hydrochloride Use in Pregnancy & Breastfeeding
  • Oxymetazoline Hydrochloride Drug Interactions
  • Oxymetazoline Hydrochloride Support Group
  • 0 Reviews for Oxymetazoline Hydrochloride - Add your own review/rating


Compare Oxymetazoline Hydrochloride with other medications


  • Eye Dryness/Redness
  • Eye Redness/Itching

No comments:

Post a Comment